Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada
News related to:Avicanna Inc · 2 min read
TORONTO, Sept. 09, 2026 /CourierPR/ -- Avicanna Inc has launched the MyMedi.ca Integrated Healthcare Program, aiming to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks. The new program extends the MyMedi.ca platform beyond traditional medical cannabis and referral channels, providing a comprehensive suite of services to hospitals, specialty clinics, multidisciplinary healthcare networks, insurers, and other healthcare organizations.
According to Aras Azadian, Chief Executive Officer of Avicanna, "An important next step in the evolution of medical cannabis is furthering integration and access within established healthcare environments." The MyMedi.ca Integrated Healthcare Program is built on a decade of research and collaboration with the Canadian medical community, focusing on providing specialized infrastructure and support to hospitals, clinics, and healthcare networks to incorporate medical cannabis into existing models of care. This program offers a focused medical cannabis formulary, pharmacist-led patient support, healthcare provider (HCP) treatment planning and education, and reimbursement and insurance options.
The MyMedi.ca Integrated Healthcare Program addresses a significant gap in medical cannabis access, as only 18% of Canadians using cannabis for medical purposes obtained their medical documents from healthcare professionals, according to Health Canada’s 2024 Canadian Cannabis Survey. This highlights the need for broader access to HCP-guided medical cannabis care while maintaining continuity with patients' existing providers. The program can be implemented across various models, including hospital and institutional cannabinoid care programs, specialty and multidisciplinary clinic partnerships, integrated referral and patient-support pathways, insurer and payer-supported patient programs, healthcare-professional education and training, and real-world evidence and research collaborations.
Avicanna’s existing infrastructure and expertise in the medical cannabis space form the backbone of the MyMedi.ca Integrated Healthcare Program. The company has developed a diverse range of proprietary products and supports four commercial stage business pillars. These include a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and active pharmaceutical ingredients (Aureus Santa Marta™). RHO Phyto offers a range of cannabinoid-based products, supported by ongoing patient and medical community education, while MyMedi.ca provides a comprehensive patient support program and services to distinct patient groups.
The MyMedi.ca Integrated Healthcare Program builds on Avicanna’s work with leading Canadian hospitals, healthcare institutions, and medical professionals on clinical research and cannabinoid access. Notable among these is the Sunnybrook Odette Cancer Centre pilot, which brought medical cannabis support into an established oncology setting and helped refine patient pathways, educational frameworks, and support models. This program aims to improve treatment outcomes by providing patients with HCP-led care, individualized treatment support, and insurance coverage.
In summary, the MyMedi.ca Integrated Healthcare Program represents a significant step forward in the integration of medical cannabis into the Canadian healthcare system, offering a comprehensive suite of services to support patients, healthcare providers, and insurers. By addressing the gap in medically guided care, this program seeks to enhance the overall healthcare experience and outcomes for patients.